About: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 1998 (uk) im Mai 1998 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en mayu de 1998 (ast) scientific article published on 01 May 1998 (en)
publication date	wds:Q74545980-1876E982-D066-4CC1-8EB5-8CE7D27656EB
publication date	1998-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74545980-75DB5401-F553-4E60-9F62-9BE8EF205861
language of work or name	English
author name string	wds:Q74545980-78ED4FDE-5834-4518-BE24-74CC6CD3A6A9 wds:Q74545980-E2045149-AE3F-4490-97B9-FFE6D34F8FD2 wds:Q74545980-F9D70843-2B7A-45DE-936D-B3C3830BCF8C
author name string	K J Pienta R L Dunn M S Strawderman
rdfs:label	Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer (en) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer (nl)
skos:prefLabel	Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer (en) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer (nl)
name	Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer (en) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer (nl)
author	wds:Q74545980-71C1A8B9-6953-4BD9-9C46-18866BCB698B
author	David C. Smith
title	wds:Q74545980-4512E3BE-C8E2-426F-ACC5-68EEBAE4244C
title	Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer (en)
page(s)	wds:Q74545980-538B247E-5034-43E6-9886-9AED2FDD7108
page(s)	1835-1843
instance of	wds:Q74545980-709FAE68-260D-4017-B1EA-CC240866136B
instance of	scholarly article
main subject	wds:Q74545980-B0D7852B-FFB4-44E5-9CC6-96CA34DD8C10
main subject	prostate cancer
PubMed ID	wds:Q74545980-E328A767-1B4E-4635-9D3E-01E865D48E94
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9586898
PubMed ID	9586898
published in	wds:Q74545980-2E6A1126-5C82-4254-B0A1-7984CF3EB010
published in	Journal of Clinical Oncology
issue	wds:Q74545980-A1D68196-7794-4C8E-913B-6943808C816C
volume	wds:Q74545980-DC6ACDAD-2336-4745-98AF-9631E98F5997
issue	5
volume	16
DOI	wds:Q74545980-378F4ADD-9D51-4D26-9118-43B89C6ED083
DOI	http://dx.doi.org/10.1200/JCO.1998.16.5.1835
DOI	10.1200/JCO.1998.16.5.1835
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74545980
is cites work of	A phase II trial of irinotecan in hormone-refractory prostate cancer MET and VEGF: synergistic targets in castration-resistant prostate cancer High-risk localized prostate cancer: primary surgery and adjuvant therapy A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer Evolving role of bone biomarkers in castration-resistant prostate cancer Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial Chemotherapy for advanced hormone refractory prostate cancer Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice Hormone-refractory Prostate Cancer Secondary hormonal manipulations in hormone refractory prostate cancer Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Changing perspectives of the role of chemotherapy in advanced prostate cancer Current strategies in the management of hormone refractory prostate cancer Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Treatment options in hormone-refractory prostate cancer: current and future approaches Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma Prostate-specific antigen and other markers of therapeutic response Recent advances in chemotherapy for advanced prostate cancer Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Prognostic indicators in hormone refractory prostate cancer Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. The patient with hormone-refractory prostate cancer: determining who, when, and how to treat Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival Highlights of contemporary issues in the medical management of prostate cancer PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials Anti-androgens and other hormonal therapies for prostate cancer Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy Systemic treatment for prostate cancer Treatment options for hormone-refractory prostate cancer Therapy of hormone-refractory prostate cancer Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study Systemic treatment and new developments in advanced prostate cancer A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 170 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software